These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11450615)

  • 41. Interfering with interferons in inflammatory bowel disease.
    Ghosh S; Chaudhary R; Carpani M; Playford R
    Gut; 2006 Aug; 55(8):1071-3. PubMed ID: 16849343
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New biological therapies in inflammatory bowel disease.
    van Deventer SJ
    Best Pract Res Clin Gastroenterol; 2003 Feb; 17(1):119-30. PubMed ID: 12617887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [3/5 Chronic intestinal inflammatory diseases].
    Blond B
    Soins; 2010 Mar; (743):59-60. PubMed ID: 20423043
    [No Abstract]   [Full Text] [Related]  

  • 44. Anti-TNF antibodies in inflammatory bowel disease: do we finally know how it works?
    Oikonomopoulos A; van Deen WK; Hommes DW
    Curr Drug Targets; 2013 Nov; 14(12):1421-32. PubMed ID: 23627866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IBD: Early use of anti-TNF agents might give a helping hand to paediatric patients with Crohn's disease.
    Smith K
    Nat Rev Gastroenterol Hepatol; 2013 Dec; 10(12):691. PubMed ID: 24217346
    [No Abstract]   [Full Text] [Related]  

  • 46. Molecular therapies in Crohn's disease: coming of age.
    Schreiber S
    Int J Colorectal Dis; 2002 Sep; 17(5):285-6. PubMed ID: 12420727
    [No Abstract]   [Full Text] [Related]  

  • 47. Interleukin-10. Cytokine synthesis inhibitory factor, SCH 52000, rIL-10, rhIL-10.
    Drugs R D; 1999 Mar; 1(3):262-4. PubMed ID: 10566041
    [No Abstract]   [Full Text] [Related]  

  • 48. Tumor necrosis factor inhibitors for inflammatory bowel disease.
    Peyrin-Biroulet L
    N Engl J Med; 2013 Dec; 369(26):2561. PubMed ID: 24369083
    [No Abstract]   [Full Text] [Related]  

  • 49. Tumor necrosis factor inhibitors for inflammatory bowel disease.
    Coskun M; Nielsen OH
    N Engl J Med; 2013 Dec; 369(26):2561-2. PubMed ID: 24369082
    [No Abstract]   [Full Text] [Related]  

  • 50. Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor-α Therapy: Pathophysiology and Clinical Implications.
    Rogler G; Biedermann L; Scharl M
    Dig Dis; 2017; 35(1-2):5-12. PubMed ID: 28147353
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bugs, TNF-alpha and IBD: more fuel for the fire.
    Greenberg GR
    Can J Gastroenterol; 2002 Feb; 16(2):127-8. PubMed ID: 11875598
    [No Abstract]   [Full Text] [Related]  

  • 52. Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance.
    Hamilton MJ; Snapper SB; Blumberg RS
    J Gastroenterol; 2012 Jan; 47(1):1-8. PubMed ID: 22215058
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New therapies for the treatment of inflammatory bowel disease.
    Sands BE
    Surg Clin North Am; 2006 Aug; 86(4):1045-64. PubMed ID: 16905423
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of Anti-Cytokine Antibodies on Gut Barrier Function.
    Liu F; Lee SA; Riordan SM; Zhang L; Zhu L
    Mediators Inflamm; 2019; 2019():7028253. PubMed ID: 31780866
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel biological strategies in inflammatory bowel diseases.
    Vermeire S; Rutgeerts P
    Inflamm Bowel Dis; 2004 Feb; 10 Suppl 1():S44-51. PubMed ID: 15168831
    [No Abstract]   [Full Text] [Related]  

  • 56. [Update on inflammatory bowel diseases].
    Watanabe M
    Nihon Naika Gakkai Zasshi; 2006 Mar; 95(3):475-8. PubMed ID: 16640077
    [No Abstract]   [Full Text] [Related]  

  • 57. Cytokine-based immunointervention in the treatment of autoimmune diseases.
    Adorini L
    Clin Exp Immunol; 2003 May; 132(2):185-92. PubMed ID: 12699404
    [No Abstract]   [Full Text] [Related]  

  • 58. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease.
    Atreya R; Neurath MF
    Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):790-802. PubMed ID: 30353856
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine.
    Felice C; Pugliese D; Guidi L
    EBioMedicine; 2019 Mar; 41():40-41. PubMed ID: 30808577
    [No Abstract]   [Full Text] [Related]  

  • 60. Transcription factor-targeted therapies in inflammatory bowel disease.
    Mitsuyama K; Suzuki A; Tomiyasu N; Takaki K; Toyonaga A; Sata M
    Digestion; 2001; 63 Suppl 1():68-72. PubMed ID: 11173913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.